{
    "Clinical Trial ID": "NCT00127933",
    "Intervention": [
        "INTERVENTION 1: ",
        "  HER2-Neu Negative",
        "  Dose and route per treatment cycle (Q3W):",
        "  Capecitabine: 825 mg/m2, orally, twice daily, days 1-14 Docetaxel: 75 mg/m2, IV infusion, day 1",
        "  HER2-neu negative: capecitabine + docetaxel",
        "  Duration: Four 3-week treatment cycles",
        "INTERVENTION 2: ",
        "  HER2-Neu Positive",
        "  Dose and route per treatment cycle (Q3W):",
        "  Capecitabine: 825 mg/m2, orally, twice daily, days 1-14 Docetaxel: 75 mg/m2, IV infusion, day 1 Trastuzumab: loading dose 4 mg/kg, 90-min IV infusion; thereafter, 2 mg/kg, 30-min IV infusion, weekly",
        "  HER2-neu positive: capecitabine + docetaxel + trastuzumab",
        "  Duration: Four 3-week treatment cycles"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  women >=18 years of age;",
        "  newly diagnosed;",
        "  infiltrating (invasive) HER2-neu-negative or HER2-neu-positive breast cancer.",
        "Exclusion Criteria:",
        "  evidence of metastatic disease, except ipsilateral (same side) axillary lymph nodes;",
        "  previous systemic or local primary treatment."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Percentage of Participants Assessed for Pathological Complete Response (pCR) Plus Near Complete (npCR) in Primary Breast Tumor at Time of Definitive Surgery",
        "  Pathological complete response was defined as the absence of histological evidence of invasive breast cancer cells in the tissue specimen removed from the breast after 4 cycles of preoperative treatment. Near pCR (npCR) was defined as the presence of invasive tumor cells with a size of 5 mm or less in aggregate in the tissue specimen removed from the breast after 4 cycles of preoperative treatment. Only pathological assessments occurring prior to the first date of adjuvant treatment were included in the analysis of pCR rate.",
        "  Time frame: at the time of definitive surgery; after four 3-week cycles (3-4 months)",
        "Results 1: ",
        "  Arm/Group Title: HER2-Neu Negative",
        "  Arm/Group Description: Dose and route per treatment cycle (Q3W):",
        "  Capecitabine: 825 mg/m2, orally, twice daily, days 1-14 Docetaxel: 75 mg/m2, IV infusion, day 1",
        "  HER2-neu negative: capecitabine + docetaxel",
        "  Duration: Four 3-week treatment cycles",
        "  Overall Number of Participants Analyzed: 101",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  15.8        (9.7 to 25.4)",
        "Results 2: ",
        "  Arm/Group Title: HER2-Neu Positive",
        "  Arm/Group Description: Dose and route per treatment cycle (Q3W):",
        "  Capecitabine: 825 mg/m2, orally, twice daily, days 1-14 Docetaxel: 75 mg/m2, IV infusion, day 1 Trastuzumab: loading dose 4 mg/kg, 90-min IV infusion; thereafter, 2 mg/kg, 30-min IV infusion, weekly",
        "  HER2-neu positive: capecitabine + docetaxel + trastuzumab",
        "  Duration: Four 3-week treatment cycles",
        "  Overall Number of Participants Analyzed: 28",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  50.0        (31.9 to 71.3)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 15/122 (12.30%)",
        "  febrile neutropenia 4/122 (3.28%)",
        "  Neutropenia 0/122 (0.00%)",
        "  Angina unstable 1/122 (0.82%)",
        "  Coronary artery disease 1/122 (0.82%)",
        "  Myocardial infarction 1/122 (0.82%)",
        "  Diarrhoea 2/122 (1.64%)",
        "  Colitis 1/122 (0.82%)",
        "  Pyrexia 2/122 (1.64%)",
        "  Chest pain 1/122 (0.82%)",
        "  Pneumonia 1/122 (0.82%)",
        "  Catheter site cellulitis 1/122 (0.82%)",
        "Adverse Events 2:",
        "  Total: 7/34 (20.59%)",
        "  febrile neutropenia 1/34 (2.94%)",
        "  Neutropenia 1/34 (2.94%)",
        "  Angina unstable 0/34 (0.00%)",
        "  Coronary artery disease 0/34 (0.00%)",
        "  Myocardial infarction 0/34 (0.00%)",
        "  Diarrhoea 0/34 (0.00%)",
        "  Colitis 0/34 (0.00%)",
        "  Pyrexia 0/34 (0.00%)",
        "  Chest pain 0/34 (0.00%)",
        "  Pneumonia 1/34 (2.94%)",
        "  Catheter site cellulitis 0/34 (0.00%)",
        "  Infection 1/34 (2.94%)"
    ]
}